Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of co-administered AD-2021 and AD-2022 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension
• Hypercholesterolemia

Drugs mentioned

• AD-2021
• AD-2022

Snippet

Sponsor: Addpharma Inc. | Conditions: Hypertension, Essential, Primary Hypercholesterolemia | Phase 3 | Status: COMPLETED